Stock Ticker

  • Loading stock data...

Cepheid Breaks Losing Streak, Gains 4% (CPHD)

Today, molecular diagnostics company Cepheid (NASDAQ: CPHD), which was on a decline after reporting a fiscal 2012 third-quarter loss and a lowered annual revenue and income guidance, went to the brink of hitting a new 52-week low price. After two successive days of declines last week, the share price opened at $30.31, a few notches […]

Egyptians Revere Isis, Investors Not So Much (ISIS)

Shares of Isis Pharmaceuticals (NASDAQ: ISIS) fell off the proverbial cliff today as shares plummeted to $10.27, a loss of $2.88 per share or 21.9% percent. The reason for the loss was one-fold as the United States Food and Drug Administration expressed a number of concerns regarding the company’s key drug, Kynamro. The FDA expressed […]

Growth Side Effects Diminish Investor Value (ISIS)

Growth may be good for a developing basketball player, but US regulators do not like to see it occur in developing drug treatments. The Food and Drug Administration (FDA) rang alarm bells over a drug, Kynamro, produced by Isis Pharmaceuticals (NASDAQ: ISIS) and Sanofi (NYSE: SNY) when neoplasms developed in conjunction with the drug’s use […]

Theravance Signs Collaboration Agreement with Merck for Cardiovascular Disease Treatment (THRX)

Biopharmaceutical company Theravance (NASDAQ: THRX) announced that it has signed a collaboration agreement with Merck for the treatment of hypertension and heart failure. As per the agreement, Theravance will receive a $5 million upfront payment, funding for research and royalties on worldwide net sales of any products arising from the collaboration. Theravance will also be […]

First Priority for Investors? Dump Delcath (DCTH)

Delcath Systems, following weeks of anticipation, announced earlier today that the FDA has accepted the company’s review application for the CHEMOSAT hepatic chemosaturation system. The application was filed on August 15. Unfortunately for Delcath, it was not granted a priority review as many investors and insiders believed would be the case. This standard review process will now […]

Lexicon Pharmaceutical’s Stock Actively Traded After Releasing New Carcinoid Treatment Drug Data (LXRX)

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares saw a dramatic rise in volume after releasing new tumor drug data. On Friday, the company released new information and clinical data about its proposed drug Telotristat. Lexicon is developing Telotristat as a treatment option for a carcinogenic condition created by tumors in the gastrointestinal tract. This carcinoid syndrome affects […]

Acacias Needn’t be Thorny Shrubs in the Sides of Investors with Gains Like Today’s (ACTG)

There is no getting past the fact that Acacia Research (NASDAQ: ACTG) is trading near its 52-week low. There is equally no sense in suggesting that its midweek gains should be ignored, scoffed at or overlooked if looking at potential growth stocks with a market capitalization of over a billion dollars. Acacia has often been, fairly […]

Hanging Like a Fish on a Clothesline (AMRN)

In Iceland, they eat a delicacy known as rotted shark, where the fish is hung out to dry for several months in preparation for human consumption. Investors may conjure up the same vision when it comes to the Food and Drug Administration’s (FDA) ongoing delays in making an exclusivity ruling on Amarin’s (NASDAQ: AMRN) prescription-grade […]

Take Two Doses in the Morning and Feel Better (QCOR)

Investors in Questcor (NASDAQ: QCOR) received a double dose of positive news this morning that helped bring a little color to what has been a dreary autumn. First, the company reported positive sales data for its H.P. Achtar Gel (Achtar), an injectable drug approved by the FDA for the treatment of 19 indications. Questcor, however, […]

The Weighting Game Has Just Begun (ARNA)

What impact will the distribution agreement that calls for Express Scripts (NASDAQ: ESRX) to sell the anti-obesity drug Qsymia, manufactured by VIVUS (NASDAQ: VVUS), have on a similar drug, Belviq, produced by Arena Pharmaceuticals (NASDAQ: ARNA)? It is a good question that will have traders digging for answers. Traders do know one thing for certain: […]

Diebold Selected as Single-Source Provider for Pharmacy Equipment Servicing (DBD)

AmerisourceBergen Technology Group (ABTG) ended its search to streamline its service delivery standards with Diebold (NYSE: DBD). ABTG selected Diebold to be its single-source provider for all of the company’s services including installations, preventative maintenance and repair. ABTG’s pharmacy automation customers will look toward Diebold to meet all of their service needs. For ABTG, this will […]

VIVUS Gains on Pact With Express Scripts For Anti-Obesity Drug (VVUS)

Biopharmaceutical company VIVUS (NASDAQ: VVUS) announced that it has entered into an agreement with the largest Pharmacy Benefit Manager (PBM) in the US, Express Scripts (NASDAQ: ESRX), to offer anti-obesity drug Qsymia, which is currently available only through mail order. The California-based VIVUS is currently developing therapies to address obesity, sleep apnea, diabetes and male […]

Lpath Opts for Reverse Stock Split to Gain NASDAQ Listing (LPTN)

In a bid to list on the NASDAQ capital market, the biotechnology company Lpath (OTC: LPTN) announced a 1-for-7 reverse stock split of the company’s Class A common stock. However, following the news, the stock price receded to $0.66 in the first hour of trading with twice the three-month average volume. The California-based Lpath focuses […]

A.P. Pharma Reapplies for FDA Approval (APPA)

Specialty pharmaceutical company A.P. Pharma (OTC: APPA) has just announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for APF530 which is the lead product candidate to be used in the prevention of chemotherapy-induced nausea and vomiting, or CINV. After resubmitting the NDA, the company is fairly […]

OncoSec Medical Gets Double Exposed (ONCS)

OncoSec Medical (OTC: ONCS) announced that it would be presenting at the 3rd Annual Cancer Immunotherapy Conference on October 4, 2012, at the New York Academy of Medicine. The conference meshes researchers, clinicians, investors and business leaders into a single day event for the purpose of exchanging information and opportunities. President and CEO Punit Dhillon will present […]

Sign Up To Get Our Latest Stocks Alerts